Study of ORIC-944 in Patients With Metastatic Prostate Cancer

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Trial Details

NCT ID
NCT05413421
Phase
PHASE1
Sponsor
ORIC Pharmaceuticals
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • ORIC-944
  • Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
  • Apalutamide (Erleada™) 60 mg or 240 mg tablets
  • Darolutamide (Nubeqa®) 300 mg tablets
  • Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Locations (sample)
  • Colorado Springs, Colorado, United States|38.83388,-104.82136
  • Plantation, Florida, United States|26.13421,-80.23184
  • Arlington Heights, Illinois, United States|42.08836,-87.98063
  • Lake Barrington, Illinois, United States|42.21252,-88.15258
  • Jeffersonville, Indiana, United States|38.27757,-85.73718

Key Eligibility Criteria

  • Patients with metastatic prostate cancer
  • Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone
  • Prior therapies:
  • Part I (single agent ORIC-944 dose escalation): Any number of prior therapies are allowed, but must have progressed after at least one line of next…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →